Overview

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH already receiving sildenafil therapy. Patients must have been receiving doses of sildenafil equal to or greater than 20 mg t.i.d. for at least 12 weeks prior to being randomized. The study continued until the predefined target number of morbidity/mortality events was reached.

Phase:

Phase 4

Details

Lead Sponsor:

Actelion

Treatments:

Bosentan
Endothelin Receptor Antagonists
Sildenafil Citrate